{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:42:59Z","timestamp":1792870979345,"version":"4.5.0"},"reference-count":117,"publisher":"American Medical Association (AMA)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,6,23]]},"abstract":"\n Importance<\/jats:title>\n Male hypogonadism is a clinical syndrome of signs and symptoms of testosterone deficiency and consistently low morning serum testosterone concentrations. The prevalence of hypogonadism due to hypothalamus, pituitary, or testes pathology is less than 1%, and the prevalence due to obesity (body mass index \u226530) is from 2% to 8%.<\/jats:p>\n <\/jats:sec>\n \n Observations<\/jats:title>\n \n The most common signs and symptoms of hypogonadism are decreased libido, decreased spontaneous erections, and small testes. Primary hypogonadism is characterized by deficient testicular production of testosterone despite elevated luteinizing hormone (LH) concentrations. The most common cause of primary hypogonadism is Klinefelter syndrome (\u22652 X chromosomes and 1 Y chromosome), which affects 2 in 1000 men and is frequently undiagnosed. Secondary hypogonadism is caused by hypothalamic or pituitary dysfunction and is characterized by low testosterone concentrations and low or inappropriately normal LH and follicle-stimulating hormone (FSH) concentrations. The most common permanent causes of secondary hypogonadism are head and neck radiation and severe head trauma. The most common potentially reversible causes of secondary hypogonadism are obesity, severe illness, and medication use (opioids, corticosteroids, checkpoint inhibitors, and medications that cause hyperprolactinemia). Testing for hypogonadism is reserved for men with signs and symptoms of androgen deficiency. Hypogonadism is confirmed if an individual\u2019s serum testosterone concentration is less than 264 to 300 ng\/dL in at least 2 fasting samples collected between 7 and 10\n am<\/jats:sc>\n and measured with an accurate and external quality-controlled assay. Assessment of calculated free testosterone concentration derived using total testosterone and sex hormone\u2013binding globulin (SHBG) concentrations is necessary for men with obesity, diabetes, and other conditions that cause low serum SHBG concentrations. Patients diagnosed with hypogonadism should have serum FSH and LH concentrations measured to distinguish primary from secondary hypogonadism. For men with obesity-induced hypogonadism, the recommended first-line management is weight loss. In men with obesity, weight loss of at least 5% typically increases serum total testosterone concentration significantly, and weight loss is associated with improved physical function, libido, and erectile function. Men with permanent hypogonadism, or those unable to discontinue medications that cause hypogonadism, may be treated with testosterone. The testosterone formulation (injection, gel, or pill) and dosage should be individualized with monitoring of serum testosterone concentration, hematocrit percentage, and possibly prostate-specific antigen concentration.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Primary hypogonadism affects less than 1% of men, whereas secondary hypogonadism due to obesity (body mass index \u226530) occurs in 2% to 8%. First-line treatment for obesity-induced hypogonadism is weight loss. Testosterone therapy should be initiated for men with permanent hypogonadism or those who are unable to discontinue medications that cause hypogonadism.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.8526","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T16:30:11Z","timestamp":1779985811000},"page":"2146","source":"Crossref","is-referenced-by-count":10,"title":["Adult Male Hypogonadism"],"prefix":"10.1001","volume":"335","author":[{"given":"Bradley D.","family":"Anawalt","sequence":"first","affiliation":[{"name":"Department of Medicine, School of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim M.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathis","family":"Grossmann","sequence":"additional","affiliation":[{"name":"Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia"},{"name":"Department of Endocrinology, Austin Health, Heidelberg, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"jrv260010r1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.5694\/mja16.00393","article-title":"Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy.","volume":"205","author":"Yeap","year":"2016","journal-title":"Med J Aust"},{"issue":"5","key":"jrv260010r2","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline.","volume":"103","author":"Bhasin","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"jrv260010r3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.juro.2018.03.115","article-title":"Evaluation and management of testosterone deficiency: AUA guideline.","volume":"200","author":"Mulhall","year":"2018","journal-title":"J Urol"},{"issue":"5","key":"jrv260010r4","doi-asserted-by":"publisher","first-page":"E234","DOI":"10.5489\/cuaj.7252","article-title":"Canadian Urological Association guideline on testosterone deficiency in men: evidence-based Q&A.","volume":"15","author":"Grober","year":"2021","journal-title":"Can Urol Assoc J"},{"issue":"12","key":"jrv260010r5","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s40618-022-01859-7","article-title":"Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE).","volume":"45","author":"Isidori","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"jrv260010r6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/cen.14633","article-title":"Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism.","volume":"96","author":"Jayasena","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"jrv260010r7","doi-asserted-by":"publisher","first-page":"508","DOI":"10.5534\/wjmh.221027","article-title":"The British Society for Sexual Medicine guidelines on male adult testosterone deficiency, with statements for practice.","volume":"41","author":"Hackett","year":"2023","journal-title":"World J Mens Health"},{"issue":"1","key":"jrv260010r8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ecl.2021.11.016","article-title":"Epidemiology of male hypogonadism.","volume":"51","author":"Thirumalai","year":"2022","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"12","key":"jrv260010r9","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1210\/jc.2003-031719","article-title":"Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study.","volume":"89","author":"Araujo","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"jrv260010r10","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.1210\/jc.2007-1245","article-title":"Prevalence of symptomatic androgen deficiency in men.","volume":"92","author":"Araujo","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"jrv260010r11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0911101","article-title":"Identification of late-onset hypogonadism in middle-aged and elderly men.","volume":"363","author":"Wu","year":"2010","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv260010r12","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4103\/aja.aja_59_20","article-title":"Prevalence of late-onset hypogonadism among middle-aged and elderly males in China: results from a national survey.","volume":"23","author":"Liu","year":"2021","journal-title":"Asian J Androl"},{"issue":"6","key":"jrv260010r13","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s11154-022-09765-2","article-title":"Aging and androgens: physiology and clinical implications.","volume":"23","author":"Anawalt","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"issue":"10","key":"jrv260010r14","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1210\/jc.2010-0864","article-title":"Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis.","volume":"95","author":"Bachman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"jrv260010r15","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/gerona\/glt154","article-title":"Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin\/hemoglobin set point.","volume":"69","author":"Bachman","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"4","key":"jrv260010r16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0378-5122(84)90015-X","article-title":"Decrease in luteinizing hormone biological activity\/immunoreactivity ratio in elderly men.","volume":"5","author":"Marrama","year":"1984","journal-title":"Maturitas"},{"issue":"6","key":"jrv260010r17","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1210\/jcem-59-6-1169","article-title":"Secretion of uncombined subunits of luteinizing hormone by gonadotroph cell adenomas.","volume":"59","author":"Snyder","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"jrv260010r18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1210\/er.2017-00025","article-title":"A reappraisal of testosterone\u2019s binding in circulation: physiological and clinical implications.","volume":"38","author":"Goldman","year":"2017","journal-title":"Endocr Rev"},{"issue":"10","key":"jrv260010r19","doi-asserted-by":"publisher","first-page":"e3536","DOI":"10.1210\/clinem\/dgaf370","article-title":"Debate about the free testosterone hypothesis: useful tool or misguided mirage?","volume":"110","author":"Anawalt","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"jrv260010r20","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1002\/hep4.2012","article-title":"Iron overload disorders.","volume":"6","author":"Hsu","year":"2022","journal-title":"Hepatol Commun"},{"issue":"1","key":"jrv260010r21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood-2018-02-830562","article-title":"Phenotypic analysis of hemochromatosis subtypes reveals variations in severity of iron overload and clinical disease.","volume":"132","author":"Sandhu","year":"2018","journal-title":"Blood"},{"issue":"5","key":"jrv260010r23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/cen.14929","article-title":"Standardising the biochemical confirmation of adult male hypogonadism: a joint position statement by the Society for Endocrinology and Association of Clinical Biochemistry and Laboratory Medicine.","volume":"101","author":"Jayasena","year":"2024","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"jrv260010r24","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1506119","article-title":"Effects of testosterone treatment in older men.","volume":"374","author":"Snyder","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv260010r25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2215025","article-title":"Cardiovascular safety of testosterone-replacement therapy.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"jrv260010r26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ahj.2021.11.016","article-title":"Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: rationale and design of the TRAVERSE study.","volume":"245","author":"Bhasin","year":"2022","journal-title":"Am Heart J"},{"issue":"4","key":"jrv260010r27","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1210\/jc.2016-2935","article-title":"Harmonized reference ranges for circulating testosterone levels in men of four cohort studies in the United States and Europe.","volume":"102","author":"Travison","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"jrv260010r28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00018-022-04562-1","article-title":"Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology.","volume":"79","author":"Narinx","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"jrv260010r29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/andr.13310","article-title":"Reference intervals for free testosterone in adult men measured using a standardized equilibrium dialysis procedure.","volume":"11","author":"Jasuja","year":"2023","journal-title":"Andrology"},{"issue":"6","key":"jrv260010r30","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/gerona\/glx170","article-title":"Evaluating calculated free testosterone as a predictor of morbidity and mortality independent of testosterone for cross-sectional and 5-year longitudinal health outcomes in older men: the Concord Health and Ageing in Men Project.","volume":"73","author":"Hsu","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"4","key":"jrv260010r31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/cen.13756","article-title":"Symptomatic androgen deficiency develops only when both total and free testosterone decline in obese men who may have incident biochemical secondary hypogonadism: prospective results from the EMAS.","volume":"89","author":"Rastrelli","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10431","key":"jrv260010r32","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.","volume":"403","author":"NCD Risk Factor Collaboration","year":"2024","journal-title":"Lancet"},{"issue":"7","key":"jrv260010r33","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1001\/jama.2024.9104","article-title":"Tirzepatide\u2014new evidence for the treatment of obesity from China.","volume":"332","author":"Jia","year":"2024","journal-title":"JAMA"},{"key":"jrv260010r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"jrv260010r35","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/andr.12770","article-title":"European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: endorsing organization: European Society of Endocrinology.","volume":"8","author":"Corona","year":"2020","journal-title":"Andrology"},{"issue":"4","key":"jrv260010r36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S2213-8587(24)00065-2","article-title":"Reversibility of congenital hypogonadotropic hypogonadism: lessons from a rare disease.","volume":"12","author":"Anawalt","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"jrv260010r37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/andr.12909","article-title":"European Academy of Andrology guidelines on Klinefelter syndrome endorsing organization: European Society of Endocrinology.","volume":"9","author":"Zitzmann","year":"2021","journal-title":"Andrology"},{"issue":"2","key":"jrv260010r38","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/andr.12951","article-title":"The European Academy of Andrology (EAA) ultrasound study on healthy, fertile men: scrotal ultrasound reference ranges and associations with clinical, seminal, and biochemical characteristics.","volume":"9","author":"Lotti","year":"2021","journal-title":"Andrology"},{"issue":"3","key":"jrv260010r39","doi-asserted-by":"publisher","first-page":"348","DOI":"10.4103\/1119-3077.113460","article-title":"Accuracy of Prader orchidometer in measuring testicular volume.","volume":"16","author":"Mbaeri","year":"2013","journal-title":"Niger J Clin Pract"},{"issue":"12","key":"jrv260010r40","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s00247-018-4195-8","article-title":"Ultrasound-based measurements of testicular volume in 6- to 16-year-old boys\u2014intra- and interobserver agreement and comparison with Prader orchidometry.","volume":"48","author":"Oehme","year":"2018","journal-title":"Pediatr Radiol"},{"issue":"1","key":"jrv260010r41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.urology.2006.09.012","article-title":"Testicular volume measurement: comparison of ultrasonography, orchidometry, and water displacement.","volume":"69","author":"Sakamoto","year":"2007","journal-title":"Urology"},{"issue":"4","key":"jrv260010r42","doi-asserted-by":"publisher","first-page":"386.e1","DOI":"10.1016\/j.jpurol.2019.04.016","article-title":"Surprising interobserver and intra-observer variability in pediatric testicular ultrasound volumes.","volume":"15","author":"Welliver","year":"2019","journal-title":"J Pediatr Urol"},{"issue":"5","key":"jrv260010r43","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1365-2265.2012.04432.x","article-title":"Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the Healthy Man Study.","volume":"77","author":"Sartorius","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"jrv260010r44","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1210\/jc.2008-1902","article-title":"The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men.","volume":"94","author":"Brambilla","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"jrv260010r45","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0079-6123(08)81006-0","article-title":"Regulation of complex pulsatile and rhythmic neuroendocrine systems: the male gonadal axis as a prototype.","volume":"181","author":"Veldhuis","year":"2010","journal-title":"Prog Brain Res"},{"issue":"7","key":"jrv260010r46","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa008","article-title":"Age and time-of-day differences in the hypothalamo-pituitary-testicular and adrenal response to total overnight sleep deprivation.","volume":"43","author":"Liu","year":"2020","journal-title":"Sleep"},{"issue":"1","key":"jrv260010r47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5271\/sjweh.3991","article-title":"Changes in melatonin and sex steroid hormone production among men as a result of rotating night shift work\u2014the HORMONIT study.","volume":"48","author":"Harding","year":"2022","journal-title":"Scand J Work Environ Health"},{"issue":"12","key":"jrv260010r48","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac153","article-title":"Endogenous diurnal patterns of adrenal and gonadal hormones during a 24-hour constant routine after simulated shift work.","volume":"6","author":"Kelly","year":"2022","journal-title":"J Endocr Soc"},{"issue":"4","key":"jrv260010r49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1365-2265.1978.tb02216.x","article-title":"Effects of oral testosterone undecanoate in hypogonadal male patients.","volume":"9","author":"Franchimont","year":"1978","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"jrv260010r50","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/BF03348281","article-title":"Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients.","volume":"3","author":"Luisi","year":"1980","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"jrv260010r51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1365-2265.1981.tb00364.x","article-title":"Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study.","volume":"14","author":"Skakkebaek","year":"1981","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"jrv260010r52","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/BF01541595","article-title":"Effects of testosterone replacement on sexual behavior in hypogonadal men.","volume":"11","author":"Salmimies","year":"1982","journal-title":"Arch Sex Behav"},{"issue":"3","key":"jrv260010r53","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1210\/jcem-57-3-557","article-title":"The nature of androgen action on male sexuality: a combined laboratory\/self-report study on hypogonadal men.","volume":"57","author":"Kwan","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"jrv260010r54","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1210\/jcem-69-4-776","article-title":"Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism.","volume":"69","author":"Finkelstein","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"jrv260010r55","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0306-4530(93)90066-T","article-title":"Psychosexual behavior in hypopituitary men: a controlled comparison of gonadotropin and testosterone replacement.","volume":"18","author":"Clopper","year":"1993","journal-title":"Psychoneuroendocrinology"},{"issue":"10","key":"jrv260010r56","first-page":"3654","article-title":"Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men\u2014a clinical research center study.","volume":"81","author":"Wang","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"jrv260010r57","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1210\/jc.82.2.407","article-title":"Testosterone replacement increases fat-free mass and muscle size in hypogonadal men.","volume":"82","author":"Bhasin","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"jrv260010r58","first-page":"4358","article-title":"Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.","volume":"81","author":"Katznelson","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"jrv260010r59","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1210\/jcem.82.8.4163","article-title":"Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.","volume":"82","author":"Behre","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"jrv260010r60","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1530\/eje.0.1380051","article-title":"Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men.","volume":"138","author":"Leifke","year":"1998","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"jrv260010r61","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1046\/j.1365-2265.2001.01271.x","article-title":"Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men.","volume":"54","author":"Wang","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"jrv260010r62","first-page":"117","article-title":"Bone mineral density in hypogonadal men remains low after long-term testosterone replacement.","volume":"4","author":"Ishizaka","year":"2002","journal-title":"Asian J Androl"},{"issue":"3","key":"jrv260010r63","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/tam.6.3.207.211","article-title":"Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel.","volume":"6","author":"Swerdloff","year":"2003","journal-title":"Aging Male"},{"issue":"5","key":"jrv260010r64","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1210\/jc.2003-032006","article-title":"Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.","volume":"89","author":"Wang","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"jrv260010r65","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1359\/JBMR.050606","article-title":"Effect of testosterone replacement on trabecular architecture in hypogonadal men.","volume":"20","author":"Benito","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"12","key":"jrv260010r66","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1507\/endocrj.EJ12-0134","article-title":"Increased frequency of anxiety, depression, quality of life and sexual life in young hypogonadotropic hypogonadal males and impacts of testosterone replacement therapy on these conditions.","volume":"59","author":"Aydogan","year":"2012","journal-title":"Endocr J"},{"issue":"1","key":"jrv260010r67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00223-022-00956-2","article-title":"Klinefelter bone microarchitecture evolution with testosterone replacement therapy.","volume":"111","author":"Piot","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"jrv260010r68","doi-asserted-by":"publisher","DOI":"10.1530\/EC-22-0112","article-title":"Testosterone in men with hypogonadism and transgender males: a systematic review comparing three different preparations.","volume":"11","author":"Madsen","year":"2022","journal-title":"Endocr Connect"},{"issue":"2","key":"jrv260010r69","first-page":"179","article-title":"Evaluation of sexual functional status and consistency of scales in patients with hypogonadotropic hypogonadism before and after testosterone replacement therapy: a single-center experience.","volume":"67","author":"Aydogan","year":"2023","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"jrv260010r70","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1210\/jc.2016-3580","article-title":"A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management.","volume":"102","author":"Grossmann","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"jrv260010r71","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/dom.70202","article-title":"Weight-reducing treatments are associated with an improvement in depression, functional health status, and quality of life: a meta-analysis of randomized controlled trials.","volume":"28","author":"Silverii","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"jrv260010r72","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13553","article-title":"The effects of weight-lowering pharmacotherapies on physical activity, function and fitness: a systematic review and meta-analysis of randomized controlled trials.","volume":"24","author":"Jobanputra","year":"2023","journal-title":"Obes Rev"},{"issue":"5","key":"jrv260010r73","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/jsxmed\/qdaf057","article-title":"Obesity and sexual desire: a systematic review and meta-analysis.","volume":"22","author":"Biernikiewicz","year":"2025","journal-title":"J Sex Med"},{"issue":"9","key":"jrv260010r74","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1111\/dom.16561","article-title":"Blood glucose and body weight reduction for the prevention of clinical events and mortality in patients with type 2 diabetes: a meta-analysis and meta-regression of 44 randomized controlled trials.","volume":"27","author":"Diallo","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"jrv260010r75","doi-asserted-by":"publisher","DOI":"10.1111\/cob.70049","article-title":"Exploring the relationship between obesity, weight loss and health-related quality of life: an updated systematic review of reviews.","volume":"16","author":"Fl\u00f8lo","year":"2026","journal-title":"Clin Obes"},{"issue":"2","key":"jrv260010r76","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/andr.13484","article-title":"Meta-analysis and construction of simple-to-use nomograms for approximating testosterone levels gained from weight loss in obese men.","volume":"12","author":"Ken-Dror","year":"2024","journal-title":"Andrology"},{"issue":"1","key":"jrv260010r77","doi-asserted-by":"publisher","DOI":"10.1111\/and.14250","article-title":"Effect of weight loss on erectile function in men with overweight or obesity: a meta-analysis of randomised controlled trials.","volume":"54","author":"Li","year":"2022","journal-title":"Andrologia"},{"issue":"6","key":"jrv260010r78","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1007\/s11695-023-06572-9","article-title":"Influence of bariatric surgery on erectile dysfunction\u2014a systematic review and meta-analysis.","volume":"33","author":"Malczak","year":"2023","journal-title":"Obes Surg"},{"issue":"8","key":"jrv260010r79","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1111\/andr.70022","article-title":"Effects of glucagon-like peptide 1 receptor agonists on testicular dysfunction: a systematic review and meta-analysis.","volume":"13","author":"Salvio","year":"2025","journal-title":"Andrology"},{"issue":"1","key":"jrv260010r80","doi-asserted-by":"publisher","first-page":"R22","DOI":"10.1093\/ejendo\/lvae071","article-title":"Testosterone therapy in older men: clinical implications of recent landmark trials.","volume":"191","author":"Grossmann","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"jrv260010r81","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1210\/jc.2016-1645","article-title":"Testosterone treatment and sexual function in older men with low testosterone levels.","volume":"101","author":"Cunningham","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"jrv260010r82","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jsxm.2018.05.008","article-title":"Validity and clinically meaningful changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: results from the Testosterone Trials.","volume":"15","author":"Wang","year":"2018","journal-title":"J Sex Med"},{"issue":"11","key":"jrv260010r83","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S2213-8587(18)30171-2","article-title":"Effect of testosterone replacement on measures of mobility in older men with mobility limitation and low testosterone concentrations: secondary analyses of the Testosterone Trials.","volume":"6","author":"Bhasin","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"jrv260010r84","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1001\/jamainternmed.2016.9540","article-title":"Association of testosterone levels with anemia in older men: a controlled clinical trial.","volume":"177","author":"Roy","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"7","key":"jrv260010r85","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jama.2016.21044","article-title":"Testosterone treatment and cognitive function in older men with low testosterone and age-associated memory impairment.","volume":"317","author":"Resnick","year":"2017","journal-title":"JAMA"},{"issue":"5","key":"jrv260010r86","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.eururo.2013.01.012","article-title":"Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.","volume":"63","author":"Yuan","year":"2013","journal-title":"Eur Urol"},{"issue":"2","key":"jrv260010r87","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1210\/clinem\/dgad484","article-title":"Effect of testosterone replacement therapy on sexual function and hypogonadal symptoms in men with hypogonadism.","volume":"109","author":"Pencina","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"jrv260010r88","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.40030","article-title":"Efficacy of testosterone replacement therapy in correcting anemia in men with hypogonadism: a randomized clinical trial.","volume":"6","author":"Pencina","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"jrv260010r89","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/jamainternmed.2016.9539","article-title":"Effect of testosterone treatment on volumetric bone density and strength in older men with low testosterone: a controlled clinical trial.","volume":"177","author":"Snyder","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"8","key":"jrv260010r90","doi-asserted-by":"publisher","first-page":"e3143","DOI":"10.1210\/clinem\/dgab149","article-title":"Effect of testosterone treatment on bone microarchitecture and bone mineral density in men: a 2-year RCT.","volume":"106","author":"Ng Tang Fui","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"jrv260010r91","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2308836","article-title":"Testosterone treatment and fractures in men with hypogonadism.","volume":"390","author":"Snyder","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv260010r92","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1056\/NEJMe2313787","article-title":"Breaking news\u2014testosterone treatment and fractures in older men.","volume":"390","author":"Grossmann","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv260010r93","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/JU.0000000000002188","article-title":"The effect of route of testosterone on changes in hematocrit: a systematic review and bayesian network meta-analysis of randomized trials.","volume":"207","author":"Nackeeran","year":"2022","journal-title":"J Urol"},{"issue":"1","key":"jrv260010r94","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S2213-8587(20)30367-3","article-title":"Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial.","volume":"9","author":"Wittert","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"18","key":"jrv260010r95","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US Preventive Services Task Force recommendation statement.","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"jrv260010r96","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JU.0000000000003491","article-title":"Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening.","volume":"210","author":"Wei","year":"2023","journal-title":"J Urol"},{"issue":"8","key":"jrv260010r97","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1210\/clinem\/dgae334","article-title":"Prostate risk and monitoring during testosterone replacement therapy.","volume":"109","author":"Bhasin","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"jrv260010r99","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.1210\/jc.2019-00806","article-title":"Prostate-specific antigen levels during testosterone treatment of hypogonadal older men: data from a controlled trial.","volume":"104","author":"Cunningham","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"jrv260010r100","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.48692","article-title":"Prostate safety events during testosterone replacement therapy in men with hypogonadism: a randomized clinical trial.","volume":"6","author":"Bhasin","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"jrv260010r101","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1210\/jc.2018-00404","article-title":"The efficacy and adverse events of testosterone replacement therapy in hypogonadal men: a systematic review and meta-analysis of randomized, placebo-controlled trials.","volume":"103","author":"Ponce","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"jrv260010r102","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-015284","article-title":"Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis.","volume":"7","author":"Elliott","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"jrv260010r103","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4103\/aja202352","article-title":"Testosterone replacement therapy and vascular thromboembolic events: a systematic review and meta-analysis.","volume":"26","author":"Cannarella","year":"2024","journal-title":"Asian J Androl"},{"issue":"6","key":"jrv260010r104","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1016\/S2666-7568(22)00096-4","article-title":"Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis.","volume":"3","author":"Hudson","year":"2022","journal-title":"Lancet Healthy Longev"},{"issue":"43","key":"jrv260010r105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/JRYT3981","article-title":"The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation.","volume":"28","author":"Cruickshank","year":"2024","journal-title":"Health Technol Assess"},{"issue":"6","key":"jrv260010r107","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1111\/andr.13779","article-title":"Single-arm study of testosterone gel replacement therapy and ambulatory blood pressure outcomes in men with hypogonadism.","volume":"13","author":"Weber","year":"2025","journal-title":"Andrology"},{"issue":"9","key":"jrv260010r108","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.eprac.2024.05.015","article-title":"Ambulatory blood pressure parameters among men with hypogonadism treated with testosterone transdermal therapy.","volume":"30","author":"Efros","year":"2024","journal-title":"Endocr Pract"},{"key":"jrv260010r109","doi-asserted-by":"publisher","DOI":"10.1177\/17562872241241864","article-title":"A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product.","volume":"16","author":"Bernstein","year":"2024","journal-title":"Ther Adv Urol"},{"issue":"9","key":"jrv260010r110","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1210\/JC.2015-1542","article-title":"Serum testosterone (T) level variability in T gel\u2013treated older hypogonadal men: treatment monitoring implications.","volume":"100","author":"Swerdloff","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"jrv260010r111","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/andr.12428","article-title":"Contributors to the substantial variation in on-treatment testosterone levels in men receiving transdermal testosterone gels in randomized trials.","volume":"6","author":"Bhasin","year":"2018","journal-title":"Andrology"},{"issue":"2","key":"jrv260010r112","doi-asserted-by":"publisher","first-page":"126","DOI":"10.7326\/M19-0882","article-title":"Testosterone treatment in adult men with age-related low testosterone: a clinical guideline from the American College of Physicians.","volume":"172","author":"Qaseem","year":"2020","journal-title":"Ann Intern Med"},{"issue":"8","key":"jrv260010r113","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1210\/js.2017-00148","article-title":"Serum testosterone concentrations remain stable between injections in patients receiving subcutaneous testosterone.","volume":"1","author":"McFarland","year":"2017","journal-title":"J Endocr Soc"},{"issue":"8","key":"jrv260010r114","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1210\/js.2019-00134","article-title":"Pharmacokinetics and acceptability of subcutaneous injection of testosterone undecanoate.","volume":"3","author":"Turner","year":"2019","journal-title":"J Endocr Soc"},{"issue":"6","key":"jrv260010r115","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1111\/jsm.12898","article-title":"Accuracy of testosterone concentrations in compounded testosterone products.","volume":"12","author":"Grober","year":"2015","journal-title":"J Sex Med"},{"issue":"2","key":"jrv260010r116","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1210\/jc.2017-02243","article-title":"The effect of testosterone on cardiovascular biomarkers in the Testosterone Trials.","volume":"103","author":"Mohler","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"jrv260010r117","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jamainternmed.2023.7862","article-title":"Effect of testosterone on progression from prediabetes to diabetes in men with hypogonadism: a substudy of the TRAVERSE randomized clinical trial.","volume":"184","author":"Bhasin","year":"2024","journal-title":"JAMA Intern Med"},{"key":"jrv260010r22","unstructured":"US Centers for Disease Control and Prevention. Hormones certified assays and participants. Accessed May 6, 2026. https:\/\/www.cdc.gov\/clinical-standardization-programs\/php\/hormones\/list-of-hormone-certified-assays.html?CDC_AAref_Val"},{"key":"jrv260010r98","unstructured":"SWOP Prostate Cancer Research Foundation, Reeuwijk. The prostate cancer risk calculators. Accessed May 6, 2026. https:\/\/www.prostatecancer-riskcalculator.com\/seven-prostate-cancer-risk-calculators"},{"key":"jrv260010r106","unstructured":"US Food and Drug Adminsitration. FDA issues class-wide labeling changes for testosterone products. Accessed May 6, 2026. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-issues-class-wide-labeling-changes-testosterone-products"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2849760\/jama_anawalt_2026_rv_260010_1781550110.19928.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:38:54Z","timestamp":1782229134000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2849760"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":117,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2026,6,23]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.8526","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}